"<img alt=\\\"Figure\\n\\\" src=\\\"emgality-ifu-100mg-pfs-7-v1.jpg\\\"/><br/></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"p02\\\"></a><span class=\\\"Bold\\\">After You Inject Your Medicine</span></p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Throw away the used prefilled syringe</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Put the used EMGALITY prefilled syringe in an FDA-cleared sharps disposal container right away after use. <span class=\\\"Bold\\\">Do not</span> throw away (dispose of) the EMGALITY prefilled syringe in your household trash.</li></ul></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><br/><a name=\\\"f18\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"emgality-ifu-100mg-pfs-8-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><dl class=\\\"Disc\\\"><dt>–</dt><dd>made of a heavy-duty plastic,</dd></dl></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><dl class=\\\"Disc\\\"><dt>–</dt><dd>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</dd></dl></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><dl class=\\\"Disc\\\"><dt>–</dt><dd>upright and stable during use,</dd></dl></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><dl class=\\\"Disc\\\"><dt>–</dt><dd>leak-resistant, and</dd></dl></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><dl class=\\\"Disc\\\"><dt>–</dt><dd>properly labeled to warn of hazardous waste inside the container.</dd></dl></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Do not</span> recycle your used sharps disposal container.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><br/>For each of the 3 injections, repeat all instructions with a new prefilled syringe.</td></tr></tbody></table><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"4.165%\\\"/><col align=\\\"left\\\" width=\\\"47.917%\\\"/><col align=\\\"left\\\" width=\\\"47.917%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Commonly Asked Questions</span></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">What if I see air bubbles in my EMGALITY prefilled syringe?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\">It is normal to have air bubbles in the prefilled syringe. EMGALITY is injected under your skin (subcutaneous injection), so these air bubbles will not harm you.</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">What if there is a drop of liquid on the tip of the needle when I remove the needle cap?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\">It is okay to see a drop of liquid on the tip of the needle.</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">What if I cannot push in the plunger?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\">If the plunger is stuck or damaged:</td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Do not</span> continue to use the syringe</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>Remove the needle from your skin</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>Dispose of the syringe and get a new one</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">What if there is a drop of liquid or blood on my skin after my injection?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\">This is normal. Press a cotton ball or gauze over the injection site. <span class=\\\"Bold\\\">Do not</span> rub the injection site.</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Q.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">How can I tell if my injection is complete?</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">A.</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\">When your injection is complete:</td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>The coral plunger rod should show through the body of the syringe.</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>The gray syringe plunger should be pushed all the way to the needle end of the syringe.</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">If you have more questions about how to use the EMGALITY prefilled syringe:</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"></td><td align=\\\"left\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>Call your healthcare provider</li></ul></td><td align=\\\"center\\\" rowspan=\\\"3\\\" valign=\\\"bottom\\\"><br/><a name=\\\"f19\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"emgality-qr-v1.jpg\\\"/></td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"></td><td align=\\\"left\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>Call 1-833-EMGALITY (1-833-364-2548)</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"></td><td align=\\\"left\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>Visit www.emgality.com</li></ul></td></tr></tbody></table><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"54.550%\\\"/><col align=\\\"left\\\" width=\\\"45.450%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" valign=\\\"top\\\"><p class=\\\"First\\\"><a name=\\\"p01\\\"></a><span class=\\\"Bold\\\">Storage and Handling Information</span></p></td><td align=\\\"right\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Store your prefilled syringes in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Your prefilled syringes may be stored out of the refrigerator in the original carton at temperatures up to 86ºF (30ºC) for up to 7 days. After storing out of the refrigerator, <span class=\\\"Bold\\\">do not</span> place EMGALITY back in the refrigerator.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Do not</span> freeze your prefilled syringes.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Keep your prefilled syringes in the carton they come in to protect them from light until time of use.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Do not</span> shake your prefilled syringes.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li>Throw away your prefilled syringes if any of the above conditions are not followed.</li></ul></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Keep your prefilled syringes and all medicines out of the reach of children.</span></li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"> </td><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Read the full Prescribing Information and Patient Information for EMGALITY inside this box to learn more about your medicine.</span></td></tr></tbody></table><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"54.000%\\\"/><col align=\\\"left\\\" width=\\\"45.000%\\\"/><col align=\\\"left\\\" width=\\\"1.000%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><br/>This Instructions for Use has been approved by the U.S. Food and Drug Administration.<br/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\">Eli Lilly and Company </td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\">Indianapolis, IN 46285, USA</td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\">US License Number 1891</td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><br/>EMGALITY<span class=\\\"Sup\\\">®</span> is a registered trademark of Eli Lilly and Company.</td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><br/>Copyright © 2019, Eli Lilly and Company. All rights reserved.</td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><br/>Issued: 06/2019</td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><br/>EMG-0001-PFS-100MG-IFU-20190604</td></tr></tbody></table></section>\",\n            \"mechanismOfAction\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s32\\\"></a><a name=\\\"section-9.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.</p></section>\",\n            \"contraindications\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34070-3\\\"><a name=\\\"s11\\\"></a><a name=\\\"section-4\\\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\\\"First\\\">EMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s13\\\">5.1</a>)]</span>.</p></section>\",\n            \"highlights\": {\n                \"dosageAndAdministration\": \"<div><ul class=\\\"Disc\\\"><li>For subcutaneous use only. (<a href=\\\"#s6\\\">2.1</a>, <a href=\\\"#s8\\\">2.2</a>, <a href=\\\"#s9\\\">2.3</a>)</li><li>Migraine recommended dosage: 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg. (<a href=\\\"#s6\\\">2.1</a>)</li><li>Episodic cluster headache recommended dosage: 300 mg (administered as three consecutive injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period. (<a href=\\\"#s8\\\">2.2</a>)</li><li>Administer in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously. (<a href=\\\"#s9\\\">2.3</a>)</li></ul></div>\"\n            }\n        }\n    },\n    {\n        \"drugName\": \"Olumiant\",\n        \"setId\": \"866e9f35-9035-4581-a4b1-75a621ab55cf\",\n        \"slug\": \"olumiant-866e9f3\",\n        \"labeler\": \"Eli Lilly and Company\",\n        \"label\": {\n            \"boxedWarning\": \"<div class=\\\"Warning\\\" id=\\\"boxed-warning\\\"><div><h2 class=\\\"Warning\\\"><span class=\\\"Bold\\\">WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS</span></h2><h2 class=\\\"Warning\\\"><span class=\\\"Bold Italics\\\">See full prescribing information for complete boxed warning.</span></h2><ul class=\\\"Disc\\\"><li><span class=\\\"Bold\\\">Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active tuberculosis. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (<a href=\\\"#s36\\\">5.1</a>)</span></li><li><span class=\\\"Bold\\\">Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (<a href=\\\"#s39\\\">5.2</a>)</span></li><li><span class=\\\"Bold\\\">Malignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (<a href=\\\"#s40\\\">5.3</a>)</span></li><li><span class=\\\"Bold\\\">Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (<a href=\\\"#s42\\\">5.4</a>)</span></li><li><span class=\\\"Bold\\\">Thrombosis has occurred in patients treated with OLUMIANT. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (<a href=\\\"#s43\\\">5.5</a>)</span></li></ul></div><div></div></div>\",\n            \"genericName\": \"baricitinib\",\n            \"labelerName\": \"Eli Lilly and Company\",\n            \"productType\": \"HUMAN PRESCRIPTION DRUG LABEL\",\n            \"effectiveTime\": \"20241113\",\n            \"title\": \"Olumiant\",\n            \"indicationsAndUsage\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34067-9\\\"><a name=\\\"s8\\\"></a><a name=\\\"section-1\\\"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s9\\\"></a><a name=\\\"section-1.1\\\"></a><p></p><h2>1.1 Rheumatoid Arthritis</h2><p class=\\\"First\\\">OLUMIANT<span class=\\\"Sup\\\">®</span> (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.</p><p><span class=\\\"Underline\\\">Limitations of Use</span>: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s10\\\"></a><a name=\\\"section-1.2\\\"></a><p></p><h2>1.2 Coronavirus Disease 2019 (COVID-19)</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s11\\\"></a><a name=\\\"section-1.3\\\"></a><p></p><h2>1.3 Alopecia Areata</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Underline\\\">Limitations of Use</span>: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.</p></div></section>\",\n            \"dosageAndAdministration\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34068-7\\\"><a name=\\\"s12\\\"></a><a name=\\\"section-2\\\"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s13\\\"></a><a name=\\\"section-2.1\\\"></a><p></p><h2>2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Prior to OLUMIANT treatment initiation, consider performing the following evaluations:</p><ul class=\\\"Disc\\\"><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Active and latent tuberculosis (TB) infection evaluation – OLUMIANT should not be given to patients with active tuberculosis (TB). If latent infection is positive in patients with rheumatoid arthritis or alopecia areata, consider treatment for TB prior to OLUMIANT use <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s36\\\">5.1</a>)]</span>.</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Viral hepatitis screening in accordance with clinical guidelines <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s36\\\">5.1</a>)]</span>.</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Complete blood count – Assess baseline values and verify whether treatment can be initiated:<dl class=\\\"Disc\\\"><dt>-</dt><dd><span class=\\\"XmChange\\\"></span>In patients with rheumatoid arthritis or alopecia areata, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) &lt;500 cells/μl, absolute neutrophil count (ANC) &lt;1000 cells/μl, or hemoglobin level &lt;8 g/dL.</dd><dt>-</dt><dd><span class=\\\"XmChange\\\"></span>In patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is &lt;200 cells/μl or if the ANC is &lt;500 cells/μl.</dd></dl><p class=\\\"First\\\">Monitor complete blood counts during treatment and modify dosage as recommended <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s17\\\">2.5</a>) and Warnings and Precautions (<a href=\\\"#s45\\\">5.7</a>)]</span>.</p></li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Baseline hepatic and renal function – Assess baseline values and monitor patients for laboratory changes. Modify dosage based on hepatic and renal impairment, and laboratory abnormalities <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s17\\\">2.5</a>) and Warnings and Precautions (<a href=\\\"#s45\\\">5.7</a>)]</span>.</li></ul><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In patients with rheumatoid arthritis or alopecia areata, update immunizations in agreement with current immunization guidelines <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s52\\\">5.9</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s14\\\"></a><a name=\\\"section-2.2\\\"></a><p></p><h2>2.2 Dosage Recommendations in Rheumatoid Arthritis</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>The recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s103\\\">12.3</a>)]</span>. An alternative administration for patients unable to swallow tablets may be used <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s31\\\">2.8</a>)]</span>. OLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s15\\\"></a><a name=\\\"section-2.3\\\"></a><p></p><h2>2.3 Dosage Recommendations in COVID-19</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>The recommended dosage of OLUMIANT for adults is 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first. An alternative administration for patients unable to swallow tablets may be used <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s31\\\">2.8</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s16\\\"></a><a name=\\\"section-2.4\\\"></a><p></p><h2>2.4 Dosage Recommendations in Alopecia Areata</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>The recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response to treatment is not adequate.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily, with or without food.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Once patients achieve an adequate response to treatment with 4 mg, decrease the dosage to 2 mg once daily.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s17\\\"></a><a name=\\\"section-2.5\\\"></a><p></p><h2>2.5 Dosage Modifications Due to Infections, Cytopenias and Anemia</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Rheumatoid Arthritis and Alopecia Areata</p><ul class=\\\"Disc\\\"><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Avoid use of OLUMIANT in patients with active, serious or opportunistic infection, including localized infections. If a patient develops a serious infection hold treatment with OLUMIANT until the infection is controlled <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s36\\\">5.1</a>)]</span>.</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Dosage modifications for patients with rheumatoid arthritis or alopecia areata and cytopenias or anemia are described in <a href=\\\"#t1\\\">Table 1</a>.</li></ul><a name=\\\"t1\\\"></a><table width=\\\"100%\\\"><caption><span>Table 1: Dosage Modifications for Cytopenias and Anemia in Patients with Rheumatoid Arthritis or Alopecia Areata</span></caption><col align=\\\"left\\\" width=\\\"33.333%\\\"/><col align=\\\"left\\\" width=\\\"22.567%\\\"/><col align=\\\"left\\\" width=\\\"44.100%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Bold\\\">Laboratory Analyte</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Laboratory Analyte Value</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Recommendation</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\"><span class=\\\"XmChange\\\"></span>Absolute Lymphocyte Count (ALC)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">≥500 cells/μL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Maintain dosage</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"XmChange\\\"></span>&lt;500 cells/μL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Interrupt OLUMIANT until ALC ≥500 cells/μL</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\"><span class=\\\"XmChange\\\"></span>Absolute Neutrophil Count (ANC)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">≥1000 cells/μL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Maintain dosage</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"XmChange\\\"></span>&lt;1000 cells/μL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Interrupt OLUMIANT until ANC ≥1000 cells/μL</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\"><span class=\\\"XmChange\\\"></span>Hemoglobin</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">≥8 g/dL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Maintain dosage</td></tr><tr class=\\\"Last\\\"><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"XmChange\\\"></span>&lt;8 g/dL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Interrupt OLUMIANT until hemoglobin ≥8 g/dL</td></tr></tbody></table><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s18\\\"></a><a name=\\\"section-2.5.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">COVID-19</span></p><ul class=\\\"Disc\\\"><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Monitor patients for signs and symptoms of new infections during treatment with OLUMIANT. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s36\\\">5.1</a>)]</span>.</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Dosage modifications for patients with COVID-19 and cytopenias are described in <a href=\\\"#t2\\\">Table 2</a>.</li></ul><a name=\\\"t2\\\"></a><table width=\\\"100%\\\"><caption><span>Table 2: Dosage Modifications for Cytopenias in Patients with COVID-19</span></caption><col align=\\\"left\\\" width=\\\"33.333%\\\"/><col align=\\\"left\\\" width=\\\"22.567%\\\"/><col align=\\\"left\\\" width=\\\"44.100%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Laboratory Analyte</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Laboratory Analyte Value</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Recommendation</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\">Absolute Lymphocyte Count (ALC)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">≥200 cells/μL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Maintain dosage</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">&lt;200 cells/μL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Interrupt OLUMIANT until ALC ≥200 cells/μL</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" rowspan=\\\"2\\\" valign=\\\"middle\\\">Absolute Neutrophil Count (ANC)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">≥500 cells/μL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Maintain dosage</td></tr><tr class=\\\"Last\\\"><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">&lt;500 cells/μL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Interrupt OLUMIANT until ANC ≥500 cells/μL</td></tr></tbody></table></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s19\\\"></a><a name=\\\"section-2.6\\\"></a><p></p><h2>2.6 Dosage Modifications for Patients with Renal Impairment or Hepatic Impairment</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s20\\\"></a><a name=\\\"section-2.6.1\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Underline\\\">Rheumatoid Arthritis</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s21\\\"></a><a name=\\\"section-2.6.2\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Italics\\\">Renal Impairment</span></p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Dosage modifications for patients with rheumatoid arthritis and renal impairment are described in <a href=\\\"#t3\\\">Table 3</a>.</p><a name=\\\"t3\\\"></a><table width=\\\"100%\\\"><caption><span>Table 3: Dosage Modifications for Patients with Rheumatoid Arthritis and Renal Impairment</span></caption><col align=\\\"left\\\" width=\\\"30.077%\\\"/><col align=\\\"left\\\" width=\\\"35.979%\\\"/><col align=\\\"left\\\" width=\\\"33.945%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Renal Impairment Stage</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Estimated Glomerular Filtration Rate (eGFR)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Recommendation</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Mild</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">60 – &lt;90 mL/minute/1.73 m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">2 mg once daily</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Moderate</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">30 - &lt;60 mL/min/1.73 m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1 mg once daily</td></tr><tr class=\\\"Last\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Severe</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">&lt;30 mL/minute/1.73 m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Not recommended</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s22\\\"></a><a name=\\\"section-2.6.3\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Italics\\\">Hepatic Impairment</span></p><ul class=\\\"Disc\\\"><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>OLUMIANT is not recommended for use in patients with severe hepatic impairment.</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Interrupt OLUMIANT, if increases in ALT or AST are observed and drug-induced liver injury (DILI) is suspected, until the diagnosis of DILI is excluded <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s46\\\">5.8</a>)].</span></li></ul></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s23\\\"></a><a name=\\\"section-2.6.4\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Underline\\\">COVID-19</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s24\\\"></a><a name=\\\"section-2.6.5\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Italics\\\">Renal Impairment</span></p><ul class=\\\"Disc\\\"><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Dosage modifications for patients with COVID-19 and renal impairment are described in <a href=\\\"#t4\\\">Table 4</a>.</li></ul><a name=\\\"t4\\\"></a><table width=\\\"100%\\\"><caption><span>Table 4: Dosage Modifications for Patients with COVID-19 and Renal Impairment</span></caption><col align=\\\"left\\\" width=\\\"40.033%\\\"/><col align=\\\"left\\\" width=\\\"36.400%\\\"/><col align=\\\"left\\\" width=\\\"23.567%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Renal Impairment Stage</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Estimated Glomerular Filtration Rate (eGFR)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Recommendation</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Mild</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">60 - &lt;90 mL/min/1.73m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4 mg once daily</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Moderate</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">30 - &lt;60 mL/min/1.73m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2 mg once daily</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Severe</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15 - &lt;30 mL/min/1.73m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1 mg once daily</td></tr><tr class=\\\"Last\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">End Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">&lt;15 mL/min/1.73m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">Not recommended</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s25\\\"></a><a name=\\\"section-2.6.6\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Italics\\\">Hepatic Impairment</span></p><ul class=\\\"Disc\\\"><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>It is not known if dosage adjustment is needed in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s46\\\">5.8</a>)]</span>.</li></ul></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s26\\\"></a><a name=\\\"section-2.6.7\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Underline\\\">Alopecia Areata</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s27\\\"></a><a name=\\\"section-2.6.8\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Italics\\\">Renal Impairment</span></p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Dosage modifications for patients with alopecia areata and renal impairment are described in <a href=\\\"#t5\\\">Table 5</a>.</p><a name=\\\"t5\\\"></a><table width=\\\"100%\\\"><caption><span>Table 5: Dosage Modifications for Patients with Alopecia Areata and Renal Impairment</span></caption><col align=\\\"left\\\" width=\\\"24.225%\\\"/><col align=\\\"left\\\" width=\\\"35.975%\\\"/><col align=\\\"left\\\" width=\\\"19.900%\\\"/><col align=\\\"left\\\" width=\\\"19.900%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Renal Impairment Stage</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Estimated Glomerular Filtration Rate (eGFR)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Recommendation</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">If the recommended dosage is<br/>2 mg once daily</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">If the recommended dosage is<br/>4 mg once daily</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Mild</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">60 – &lt;90 mL/minute/1.73 m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"middle\\\">Maintain dosage</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Moderate</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">30 – &lt;60 mL/min/1.73 m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Reduce to 1 mg once daily</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">Reduce to 2 mg once daily</td></tr><tr class=\\\"Last\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Severe</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">&lt;30 mL/minute/1.73 m<span class=\\\"Sup\\\">2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"middle\\\">Not recommended</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s28\\\"></a><a name=\\\"section-2.6.9\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Italics\\\">Hepatic Impairment</span></p><ul class=\\\"Disc\\\"><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>OLUMIANT is not recommended for use in patients with severe hepatic impairment.</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s46\\\">5.8</a>)].</span></li></ul></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s29\\\"></a><a name=\\\"section-2.7\\\"></a><p></p><h2>2.7 Dosage Modifications Due to Drug Interactions</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s30\\\"></a><a name=\\\"section-2.7.1\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Underline\\\">Rheumatoid Arthritis, COVID-19 or Alopecia Areata</span></p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>The recommended dosage of OLUMIANT in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors, such as probenecid, are shown in <a href=\\\"#t6\\\">Table 6</a><span class=\\\"Italics\\\">[see Drug Interactions (<a href=\\\"#s74\\\">7.1</a>) and Clinical Pharmacology (<a href=\\\"#s103\\\">12.3</a>)]</span>.</p><a name=\\\"t6\\\"></a><table width=\\\"100%\\\"><caption><span>Table 6: Dosage Modifications when Coadministered with Strong OAT3 Inhibitors in Patients With Rheumatoid Arthritis, COVID-19 or Alopecia Areata</span></caption><col align=\\\"left\\\" width=\\\"25.200%\\\"/><col align=\\\"left\\\" width=\\\"74.800%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Concomitant Medication</span></td><td align=\\\"left\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Recommendation</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" rowspan=\\\"3\\\" valign=\\\"top\\\"><br/>Strong OAT3 inhibitors (e.g., probenecid)</td><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">If the recommended dosage is 4 mg once daily, reduce dosage to 2 mg once daily.</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">If the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily.</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">If the recommended dosage is 1 mg once daily, consider discontinuing probenecid.</td></tr></tbody></table></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s31\\\"></a><a name=\\\"section-2.8\\\"></a><p></p><h2>2.8 Alternative Administration for Patients Unable to Swallow Tablets</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>For patients who are unable to swallow whole tablets, an alternative mode of administration may be considered:</p><ul class=\\\"Disc\\\"><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Oral dispersion</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Gastrostomy tube (G tube)</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Nasogastric tube (NG tube) or orogastric tube (OG tube)</li></ul><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Intact tablets are not hazardous. Tablets may be crushed to facilitate dispersion. It is not known if powder from the crushed tablets may constitute a reproductive hazard to the preparer. If tablets are crushed, use proper control measures (e.g., ventilated enclosure) or personal protective equipment (i.e., N95 respirator). Dispersed tablets are stable in water for up to 4 hours.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s32\\\"></a><a name=\\\"section-2.8.1\\\"></a><p></p><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Underline\\\">Preparation Instructions for Alternative Administration</span>:</p><ul class=\\\"Disc\\\"><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Italics\\\">Oral administration of dispersed tablets in water:</span> For patients who are unable to swallow whole tablets, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 10 mL (5 mL minimum) of room temperature water, dispersed by gently swirling the tablet(s) and immediately taken orally. The container should be rinsed with an additional 10 mL (5 mL minimum) of room temperature water and the entire contents swallowed by the patient (<a href=\\\"#t7\\\">Table 7</a>).</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Italics\\\">Administration via G tube:</span> For patients with a G tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 15 mL (10 mL minimum) of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw entire contents from the container into an appropriate syringe and immediately administer through the gastric feeding tube. Rinse container with approximately 15 mL (10 mL minimum) of room temperature water, withdraw the contents into the syringe, and administer through the tube (<a href=\\\"#t7\\\">Table 7</a>).</li><li style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Italics\\\">Administration via NG or OG tube:</span> For patients with a NG or OG tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or a combination of tablets necessary to achieve the desired dose up to 4-mg may be placed into a container with approximately 30 mL of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw the entire contents from the container into an appropriate syringe and immediately administer through the enteral feeding tube. To avoid clogging of small diameter tubes (smaller than 12 Fr), the syringe can be held horizontally and shaken during administration. Rinse container with a sufficient amount (minimum of 15 mL) of room temperature water, withdraw the contents into the syringe, and administer through the tube (<a href=\\\"#t7\\\">Table 7</a>).</li></ul><a name=\\\"t7\\\"></a><table width=\\\"100%\\\"><caption><span>Table 7: Dispersion and Rinse Volume for Alternative Administration</span></caption><col align=\\\"left\\\" width=\\\"39.633%\\\"/><col align=\\\"left\\\" width=\\\"29.667%\\\"/><col align=\\\"left\\\" width=\\\"30.700%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"XmChange\\\"></span><span class=\\\"Bold\\\">Administration via</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Dispersion Volume</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Container Rinse Volume</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"XmChange\\\"></span>Oral dispersion</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">10 mL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">10 mL</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"XmChange\\\"></span>G tube</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">15 mL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">15 mL</td></tr><tr class=\\\"Last\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"XmChange\\\"></span>NG tube<br/>or OG tube</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">30 mL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">15 mL</td></tr></tbody></table></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"43678-2\\\"><a name=\\\"s33\\\"></a><a name=\\\"section-2.9\\\"></a><p></p><h2>3 DOSAGE FORMS AND STRENGTHS</h2><p class=\\\"First\\\">OLUMIANT is available as debossed, film-coated tablets:</p><ul class=\\\"Disc\\\"><li>1 mg tablet contains a recessed area on each face of the tablet surface, is very light pink, round, debossed with “Lilly” on one side and “1” on the other.</li><li>2 mg tablet contains a recessed area on each face of the tablet surface, is light pink, oblong, debossed with “Lilly” on one side and “2” on the other.</li><li>4 mg tablet contains a recessed area on each face of the tablet surface, is medium pink, round, debossed with “Lilly” on one side and “4” on the other.</li></ul></div></section>\",\n            \"dosageFormsAndStrengths\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43678-2\\\"><a name=\\\"s33\\\"></a><a name=\\\"section-2.9\\\"></a><p></p><h2>3 DOSAGE FORMS AND STRENGTHS</h2><p class=\\\"First\\\">OLUMIANT is available as debossed, film-coated tablets:</p><ul class=\\\"Disc\\\"><li>1 mg tablet contains a recessed area on each face of the tablet surface, is very light pink, round, debossed with “Lilly” on one side and “1” on the other.</li><li>2 mg tablet contains a recessed area on each face of the tablet surface, is light pink, oblong, debossed with “Lilly” on one side and “2” on the other.</li><li>4 mg tablet contains a recessed area on each face of the tablet surface, is medium pink, round, debossed with “Lilly” on one side and “4” on the other.</li></ul></section>\",\n            \"warningsAndPrecautions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43685-7\\\"><a name=\\\"s35\\\"></a><a name=\\\"section-4\\\"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s36\\\"></a><a name=\\\"section-4.1\\\"></a><p></p><h2>5.1 Serious Infections</h2><p class=\\\"First\\\">Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients with rheumatoid arthritis receiving OLUMIANT. The most common serious infections reported with OLUMIANT included pneumonia, herpes zoster, and urinary tract infection <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s54\\\">6.1</a>)]</span>. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with OLUMIANT. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids.</p><p>Avoid use of OLUMIANT in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating OLUMIANT in patients:</p><ul class=\\\"Disc\\\"><li>with chronic or recurrent infection</li><li>who have been exposed to tuberculosis</li><li>with a history of a serious or an opportunistic infection</li><li>who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or</li><li>with underlying conditions that may predispose them to infection.</li></ul><p>In patients with rheumatoid arthritis or alopecia areata, closely monitor for the development of signs and symptoms of infection during and after treatment with OLUMIANT. Interrupt OLUMIANT in patients with rheumatoid arthritis or alopecia areata, if the patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment with OLUMIANT should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and OLUMIANT should be interrupted if the patient is not responding to therapy. Do not resume OLUMIANT until the infection is controlled.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In patients with COVID-19, monitor for signs and symptoms of new infections during and after treatment with OLUMIANT. There is limited information regarding the use of OLUMIANT in patients with COVID-19 and concomitant active serious infections. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s37\\\"></a><a name=\\\"section-4.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Tuberculosis</span></p><p>Evaluate patients for active infection prior to administration of OLUMIANT. OLUMIANT should not be given to patients with active TB.</p><p>Test patients with rheumatoid arthritis or alopecia areata for latent tuberculosis. Patients with rheumatoid arthritis or alopecia areata and latent tuberculosis (TB) should be treated with standard antimycobacterial therapy before initiating OLUMIANT. Consider anti-TB therapy prior to initiation of OLUMIANT in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.</p><p>During OLUMIANT use, monitor patients for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s38\\\"></a><a name=\\\"section-4.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Viral Reactivation</span></p><p>Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with OLUMIANT. If a patient develops herpes zoster, interrupt OLUMIANT treatment until the episode resolves.</p><p>The impact of OLUMIANT on chronic viral hepatitis reactivation is unknown. Patients with evidence of active hepatitis B or C infection were excluded from clinical trials. In clinical trials in patients with rheumatoid arthritis or alopecia areata, patients who were positive for hepatitis C antibody but negative for hepatitis C virus RNA were permitted to enroll. Patients with positive hepatitis B surface antibody and hepatitis B core antibody, without hepatitis B surface antigen, were permitted to enroll; such patients should be monitored for expression of hepatitis B virus (HBV) DNA. Should HBV DNA be detected, consult with a hepatologist. Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy with OLUMIANT.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s39\\\"></a><a name=\\\"section-4.2\\\"></a><p></p><h2>5.2 Mortality</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed in patients treated with the JAK inhibitor compared with TNF blockers. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s40\\\"></a><a name=\\\"section-4.3\\\"></a><p></p><h2>5.3 Malignancy and Lymphoproliferative Disorders</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Malignancies were observed in clinical studies of OLUMIANT <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s54\\\">6.1</a>)]</span>.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients with a known malignancy (other than successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s41\\\"></a><a name=\\\"section-4.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Non-melanoma skin cancers</span></p><p>Non-melanoma skin cancers (NMSCs) have been reported in patients treated with OLUMIANT. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s42\\\"></a><a name=\\\"section-4.4\\\"></a><p></p><h2>5.4 Major Adverse Cardiovascular Events</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of major adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s43\\\"></a><a name=\\\"section-4.5\\\"></a><p></p><h2>5.5 Thrombosis</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with OLUMIANT. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>If clinical features of DVT/PE or arterial thrombosis occur, patients should discontinue OLUMIANT and be evaluated promptly and treated appropriately. Avoid OLUMIANT in patients that may be at increased risk of thrombosis.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s44\\\"></a><a name=\\\"section-4.6\\\"></a><p></p><h2>5.6 Hypersensitivity</h2><p class=\\\"First\\\">Reactions such as angioedema, urticaria, and rash that may reflect drug hypersensitivity have been observed in patients receiving OLUMIANT, including serious reactions. If a serious hypersensitivity reaction occurs, promptly discontinue OLUMIANT while evaluating the potential causes of the reaction <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s72\\\">6.2</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s45\\\"></a><a name=\\\"section-4.7\\\"></a><p></p><h2>5.7 Gastrointestinal Perforations</h2><p class=\\\"First\\\">Gastrointestinal perforations have been reported in clinical studies with OLUMIANT.</p><p>Monitor OLUMIANT-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Evaluate promptly patients presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s46\\\"></a><a name=\\\"section-4.8\\\"></a><p></p><h2>5.8 Laboratory Abnormalities</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s47\\\"></a><a name=\\\"section-4.8.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Neutropenia</span> – Treatment with OLUMIANT was associated with an increased incidence of neutropenia (ANC less than 1000 cells/mm<span class=\\\"Sup\\\">3</span>) compared to placebo.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ANC less than 1000 cells/mm<span class=\\\"Sup\\\">3</span>.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ANC less than 1000 cells/mm<span class=\\\"Sup\\\">3</span>. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ANC less than 500 cells/mm<span class=\\\"Sup\\\">3</span>.</p><p>Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ANC <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s13\\\">2.1</a>, <a href=\\\"#s17\\\">2.5</a>) and Adverse Reactions (<a href=\\\"#s54\\\">6.1</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s48\\\"></a><a name=\\\"section-4.8.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Lymphopenia</span> – ALC less than 500 cells/mm<span class=\\\"Sup\\\">3</span> were reported in OLUMIANT clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with OLUMIANT, but not placebo.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ALC less than 500 cells/mm<span class=\\\"Sup\\\">3</span>.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ALC less than 200 cells/mm<span class=\\\"Sup\\\">3</span>. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ALC less than 200 cells/mm<span class=\\\"Sup\\\">3</span>.</p><p>Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ALC <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s13\\\">2.1</a>, <a href=\\\"#s17\\\">2.5</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s49\\\"></a><a name=\\\"section-4.8.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Anemia</span> – Decreases in hemoglobin levels to less than 8 g/dL were reported in OLUMIANT clinical trials. In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with hemoglobin less than 8 g/dL. Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on hemoglobin levels <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s13\\\">2.1</a>, <a href=\\\"#s17\\\">2.5</a>)]</span>.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with hemoglobin less than 8 g/dL.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s50\\\"></a><a name=\\\"section-4.8.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Liver Enzyme Elevations</span> – Treatment with OLUMIANT was associated with increased incidence of liver enzyme elevation compared to placebo. Increases of ALT ≥5 times the upper limit of normal (ULN) and increases of AST ≥10 times the ULN were observed in patients in OLUMIANT clinical trials. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt OLUMIANT until this diagnosis is excluded <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s54\\\">6.1</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s51\\\"></a><a name=\\\"section-4.8.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Lipid Elevations</span> – Treatment with OLUMIANT was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Assessment of lipid parameters should be performed approximately 12 weeks following OLUMIANT initiation in patients with rheumatoid arthritis or alopecia areata <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s54\\\">6.1</a>)]</span>. Manage patients according to clinical guidelines for the management of hyperlipidemia.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s52\\\"></a><a name=\\\"section-4.9\\\"></a><p></p><h2>5.9 Vaccinations</h2><p class=\\\"First\\\">Avoid use of live vaccines with OLUMIANT. Update immunizations in patients with rheumatoid arthritis or alopecia areata prior to initiating OLUMIANT therapy in agreement with current immunization guidelines.</p></div></section>\",\n            \"adverseReactions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34084-4\\\"><a name=\\\"s53\\\"></a><a name=\\\"section-5\\\"></a><p></p><h1>6 ADVERSE REACTIONS</h1><p class=\\\"First\\\">The following clinically significant adverse reactions are described elsewhere in the labeling:</p><ul class=\\\"Disc\\\"><li>Serious Infections <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s36\\\">5.1</a>)]</span></li><li>Mortality <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s39\\\">5.2</a>)]</span></li><li>Malignancy and Lymphoproliferative Disorders <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s40\\\">5.3</a>)]</span></li><li>Major Adverse Cardiovascular Events <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s42\\\">5.4</a>)]</span></li><li>Thrombosis <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s43\\\">5.5</a>)]</span></li><li>Hypersensitivity <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s44\\\">5.6</a>)]</span></li><li>Gastrointestinal Perforations <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s45\\\">5.7</a>)]</span></li><li>Laboratory Abnormalities <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s46\\\">5.8</a>)]</span></li></ul><div class=\\\"Section\\\" data-sectioncode=\\\"90374-0\\\"><a name=\\\"s54\\\"></a><a name=\\\"section-5.1\\\"></a><p></p><h2>6.1 Clinical Trials Experience</h2><p class=\\\"First\\\">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s55\\\"></a><a name=\\\"section-5.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Bold\\\">Adverse Reactions in Patients with Rheumatoid Arthritis</span></p><p>The safety of OLUMIANT was evaluated in six randomized double-blind placebo-controlled studies (three Phase 2, three Phase 3) and a long-term extension study in patients with moderately to severely active RA. Patients were randomized to placebo (1070 patients), OLUMIANT 2 mg (479 patients), or baricitinib 4 mg (997 patients).</p><p>Patients could be switched to baricitinib 4 mg from placebo or OLUMIANT 2 mg from as early as Week 12 depending on the study design. All patients initially randomized to placebo were switched to baricitinib 4 mg by Week 24.</p><p>During the 16-week treatment period, adverse events leading to discontinuation of treatment were reported by 35 patients (11.4 per 100 patient-years) treated with placebo, 17 patients (12.1 per 100 patient-years) with OLUMIANT 2 mg, and 40 patients (13.4 per 100 patient-years) treated with baricitinib 4 mg.</p><p>During 0 to 52-week exposure, adverse events leading to discontinuation of treatment were reported by 31 patients (9.2 per 100 patient-years) with OLUMIANT 2 mg, and 92 patients (10.2 per 100 patient-years) treated with baricitinib 4 mg.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s56\\\"></a><a name=\\\"section-5.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Overall Infections</span> – During the 16-week treatment period, infections were reported by 253 patients (82.1 per 100 patient-years) treated with placebo, 139 patients (99.1 per 100 patient-years) treated with OLUMIANT 2 mg, and 298 patients (100.1 per 100 patient-years) treated with baricitinib 4 mg.</p><p>During 0 to 52-week exposure, infections were reported by 200 patients (5"